Articles from Aztiq Consulting ehf.

REYKJAVIK, Iceland and LONDON, July 18, 2025 (GLOBE NEWSWIRE) -- Aztiq has sold the majority of its share in Adalvo to EQT, a global investment organization that owns a portfolio of companies and assets in Europe, Asia Pacific and the Americas. Adalvo was founded by Aztiq in 2018 and is one of the leading business-to-business pharmaceutical companies in Europe, with more than 280 employees, and 170 commercial partnerships globally in more than 140 countries.

REYKJAVIK, Iceland and MORRISTOWN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Alvogen Pharma US, Inc. (“Alvogen” or the “Company”), a privately owned US-based pharmaceutical company, has completed a comprehensive refinancing of its capital structure. Alvogen raised a $553 million first lien term loan due 2028 (the “First Lien Term Loan”) and a $116 million second lien term loan due 2029 (the “Second Lien Term Loan”) to refinance its existing secured term loan due 2025. Overall, the new term loans reduce debt by approximately $60 million and represent approximately 1.4 times Alvogen’s 2024 EBITDA.

LONDON and BANGKOK, Thailand, July 03, 2023 (GLOBE NEWSWIRE) -- Aztiq Pharma Partners (“Aztiq”), a private equity company focused on the life sciences sector, and Innobic (Asia) Company Limited (“Innobic”), the life science arm of Thai oil and gas conglomerate PTT Public Company Limited (“PTT”) (collectively, “the shareholders”), today announced the pricing of a sale of 25,095,850 shares of Lotus Pharmaceuticals (1795:TT; “Lotus,” “the company”), a multinational pharmaceutical company, at a price of NT$297 per share. The trade will be settled on July 5, 2023, subject to satisfaction of customary settlement procedures. The sale is being executed by Alvogen Emerging Market Holdings Limited (“AEMH”), which will continue to own 41% of Lotus common stock after the close of the transaction. Inclusive of Innobic’s direct holdings of Lotus, the shareholders will continue to own approximately 47.7% of the company.

TOKYO and LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Mitsui & Co., Ltd. ("Mitsui") has acquired convertible bonds worth approximately US $62.75 million (¥8.6 billion) issued by Luxembourg-based Alvotech S.A. (“Alvotech”) from ATP Holdings ehf, an affiliate of Aztiq Pharma Partners Sarl (“Aztiq”). Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide. Biosimilar medicines are therapeutic equivalents to biologics, a class of medicines that have revolutionized the management of many difficult-to-treat medical conditions. Biosimilars have the potential to expand patient access to biologic medicines globally by providing these critical treatments at a lower cost. Biologic medicines have gained considerable importance in recent years and constituted 59% of novel active substances approved in 20221.